Clarkston Capital Partners, LLC, is an independent investment firm that studies the risks of investment opportunities before considering the possible returns. The firm does so in order to understand the business fundamentals and to help protect investors. The company submitted its SEC 13F filings on October 13, 2014, for the third financial quarter ended September 30, 2014. The filings indicate that the company’s top holdings are Procter & Gamble Co (NYSE:PG), SYSCO Corporation (NYSE:SYY), and Johnson & Johnson (NYSE:JNJ).
The firm’s filings showed that Procter & Gamble Co (NYSE:PG) was its biggest investment with an investment value of $16.96 million. Procter & Gamble Co is a renowned producer of consumer goods such as fabric, hair, health, beauty and related products. The company, also known as P&G, is currently undergoing a restructuring phase, offering buyouts to its managers and doing away with some jobs that it feels aren’t quite essential at this juncture. The Cincinnati, Ohio-based company is also planning to sell out some of its brands to concentrate its efforts on the most profitable ones. Some of its subsidiaries include Max Factor, Braun, Gillete, and more.
SYSCO Corporation (NYSE:SYY) came out as the second largest investment of Clarkston Capital Partners, accounting for an investment value of $14.69 million. Sysco is a multinational company that markets and distributes food products to restaurants, health care and educational facilities. The company’s quarter one of 2015 adjusted earnings beat that of Zacks Consensus Estimate by 4%. The new earnings is 52 cents, compared to 50 cents by the consensus estimate. The company is currently working on a plan to acquire US Foods for a total sum of $3.5 billion. A few of the company’s subsidiaries are Pallas Foods, SYGMA Network Inc, FreshPoint, and Malcom Meats. It’s top three shareholders are Yacktman Asset Management LP (5.44%), SSgA Funds Management, Inc. (5.13%), and The Vanguard Group, Inc. (4.99%).
Johnson & Johnson (NYSE:JNJ) emerged as the third largest investment of Clarkston Capital Partners with an investment value of $14.68 million. The company is a multinational medical devices, consumer goods, and pharmaceutical products manufacturer. The company is currently working on an Ebola vaccine and has pledged $200 million to accelerate the project. The company is the owner of DePuy, Janssen Pharmaceutica, Ethicon Inc, Neutrogena, among several other subsidiaries. Its top institutional shareholders are Vanguard Group, Inc., State Street Corp, and BlackRock Fund Advisors.
This article has been written by Victor Ochieng.
